Medicare AdvantageCoverageMedium impact
MA08.088e, Ocrelizumab (Ocrevus®) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo™)
Independence Blue Cross·Neurology, Oncology, Rheumatology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.088e for Ocrelizumab (Ocrevus) and Ocrelizumab with Hyaluronidase-ocsq (Ocrevus Zunovo) has been updated effective October 1, 2025. This affects coverage and billing requirements for these multiple sclerosis medications under Medicare Advantage plans.
Action Required
Immediately: Review updated Medicare Advantage policy MA08.088e for Ocrelizumab coverage requirements. Verify current prior authorization and documentation requirements for Ocrevus and Ocrevus Zunovo before billing Medicare Advantage plans. Contact IBX or check the policy URL for specific coverage criteria changes.